Myelodysplastic Syndromes
December 2019 Issue

Nearly every major medical breakthrough over the past 50 years can be attributed to new discoveries that were made possible through meticulous biomedical research. Many diseases and conditions that previously took a heavy toll on patients in terms of both morbidity and mortality are now either treatable or preventable thanks in large part to painstaking research that expanded the frontiers of scientific knowledge and moved the most promising basic research developments into tangible health benefits through human clinical trails. Ongoing research is also the key that will open the door to additional major medical advances and breakthroughs in the future.

Our staff at Medifocus is committed to keeping our subscribers to the Medifocus Digest Alert on Myelodysplastic Syndromes abreast of the latest new research developments that have recently been published in the medical literature for this condition. In this issue of the Digest Alert, you will find a focused list of hand-picked journal article references that represent the latest advances in basic and clinical research for Myelodysplastic Syndromes. These articles represent the current state-of-the-art of the research that will hopefully lead to additional major advances and breakthroughs in the clinical management of Myelodysplastic Syndromes. You can access the summaries of each article referenced below by simply clicking on the article Title.

We will continue to update you with the latest scientific and clinical developments through the Medifocus Digest Alert on Myelodysplastic Syndromes every 3 months. Thank you for your ongoing subscription to this publication.

Elliot Jacob, Ph.D.
Vice-President - Content, Inc.

1:The efficacy and toxicity of the CHG priming regimen (low-dose cytarabine, homoharringtonine, and G-CSF) in higher risk MDS patients relapsed or refractory to decitabine.
Authors:Xiu C, Li X, Wu L, Xu F, He Q, Zhang Z, Wu D, Song L, Su J, Zhou L, Zhao Y, Tao Y, Chang C
Institution:Department of Hematology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, 200233, China. Hospital, Shanghai, 200233, China.
Journal:J Cancer Res Clin Oncol. 2019 Dec;145(12):3089-3097. doi: 10.1007/s00432-019-03031-w. Epub 2019 Sep 26.

2:Guadecitabine (SGI-110): an investigational drug for the treatment of myelodysplastic syndrome and acute myeloid leukemia.
Authors:Daher-Reyes GS, Merchan BM, Yee KWL
Institution:Division of Medical Oncology and Hematology, University Health Network - Princess Margaret Cancer Centre , Toronto , Ontario , Canada.
Journal:Expert Opin Investig Drugs. 2019 Oct;28(10):835-849. doi: 10.1080/13543784.2019.1667331. Epub 2019 Sep 19.

3:Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study.
Authors:Ravandi F, Assi R, Daver N, Benton CB, Kadia T, Thompson PA, Borthakur G, Alvarado Y, Jabbour EJ, Konopleva M, Takahashi K, Kornblau S, DiNardo CD, Estrov Z, Flores W, Basu S, Allison J, Sharma P, Pierce S, Pike A, Cortes JE, Garcia-Manero G, Kantarjian HM
Institution:Department of Leukaemia, the University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address:; Department of Leukaemia, the University of Texas MD Anderson Cancer Center, Houston, TX, USA; Lebanese American University, Gilbert and Rose-Marie Chagoury School of Medicine, Beirut, Lebanon; Lebanese American University Medical Center-Rizk Hospital, Beirut, Lebanon.
Journal:Lancet Haematol. 2019 Sep;6(9):e480-e488. doi: 10.1016/S2352-3026(19)30114-0. Epub 2019 Aug 7.

4:The incidence, risk factors, and survival of acute myeloid leukemia secondary to myelodysplastic syndrome: A population-based study.
Authors:Ye X, Chen D, Zheng Y, Wu C, Zhu X, Huang J
Institution:Department of Hematology, The Fourth Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of China.; Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of China.
Journal:Hematol Oncol. 2019 Oct;37(4):438-446. doi: 10.1002/hon.2660. Epub 2019 Sep 6.

5:The Yin and Yang of myelodysplastic syndromes and autoimmunity: The paradox of autoimmune disorders responding to therapies specific for MDS.
Authors:Fozza C, La Nasa G, Caocci G
Institution:Hematology Unit, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Viale San Pietro 12, 07100 Sassari, Italy. Electronic address: Cagliari, Italy. Cagliari, Italy.
Journal:Crit Rev Oncol Hematol. 2019 Oct;142:51-57. doi: 10.1016/j.critrevonc.2019.07.018. Epub 2019 Jul 26.

6:Hematologic improvement with iron chelation therapy in myelodysplastic syndromes: Clinical data, potential mechanisms, and outstanding questions.
Authors:Leitch HA, Gattermann N
Institution:Hematology, St. Paul's Hospital and the University of British Columbia, Vancouver, BC, Canada. Electronic address: Dusseldorf, Germany.
Journal:Crit Rev Oncol Hematol. 2019 Sep;141:54-72. doi: 10.1016/j.critrevonc.2019.06.002. Epub 2019 Jun 10.

7:Genetic abnormalities and pathophysiology of MDS.
Authors:Hosono N
Institution:Division of Hematology and Oncology, University of Fukui, Matsuokashimoaizuki 23-3, Eiheiji, Fukui, 910-1193, Japan.
Journal:Int J Clin Oncol. 2019 Aug;24(8):885-892. doi: 10.1007/s10147-019-01462-6. Epub 2019 May 15.

8:Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial.
Authors:Garcia-Manero G, Roboz G, Walsh K, Kantarjian H, Ritchie E, Kropf P, O'Connell C, Tibes R, Lunin S, Rosenblat T, Yee K, Stock W, Griffiths E, Mace J, Podoltsev N, Berdeja J, Jabbour E, Issa JJ, Hao Y, Keer HN, Azab M, Savona MR
Institution:The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: USA. Philadelphia, PA, USA. Nashville, TN, USA.
Journal:Lancet Haematol. 2019 Jun;6(6):e317-e327. doi: 10.1016/S2352-3026(19)30029-8. Epub 2019 May 3.

9:Factors predicting early mortality after new diagnosis of myelodysplastic syndrome: A population-based study.
Authors:Jacobsen AM, Poynter JN, Richardson MR, Nguyen PL, Hirsch B, Cioc A, Roesler MA, Warlick ED
Institution:Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, Minnesota. Minneapolis, Minnesota. Minneapolis, Minnesota.
Journal:Eur J Haematol. 2019 Jul;103(1):56-63. doi: 10.1111/ejh.13243. Epub 2019 May 16.

10:An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study.
Authors:Savona MR, Odenike O, Amrein PC, Steensma DP, DeZern AE, Michaelis LC, Faderl S, Harb W, Kantarjian H, Lowder J, Oganesian A, Azab M, Garcia-Manero G
Institution:Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN, USA. Electronic address: Houston, TX, USA. Houston, TX, USA.
Journal:Lancet Haematol. 2019 Apr;6(4):e194-e203. doi: 10.1016/S2352-3026(19)30030-4.

11:Efficacy of granulocyte colony stimulating factor in combination with erythropoiesis stimulating agents for treatment of anemia in patients with lower risk myelodysplastic syndromes: A systematic review.
Authors:Affentranger L, Bohlius J, Hallal M, Bonadies N
Institution:Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, Switzerland. University Hospital, University of Bern, Switzerland; Department for BioMedical Research, University of Bern, Switzerland. University Hospital, University of Bern, Switzerland; Department for BioMedical Research, University of Bern, Switzerland. Electronic address:
Journal:Crit Rev Oncol Hematol. 2019 Apr;136:37-47. doi: 10.1016/j.critrevonc.2019.01.021. Epub 2019 Feb 15.

12:Adverse transfusion reactions in patients with aplastic anaemia or myelodysplastic syndromes.
Authors:Moncharmont P, Quittancon E, Barday G, Benamara A
Institution:Department of Vigilance, Haemovigilance, Site de Lyon Decines, Etablissement francais du Sang Auvergne Rhone-Alpes, Decines-Charpieu Cedex, France.
Journal:Vox Sang. 2019 May;114(4):349-354. doi: 10.1111/vox.12765. Epub 2019 Feb 28.

For a FREE PREVIEW of the Medifocus Guidebook on Myelodysplastic Syndromes click here

To purchase a copy of the COMPLETE Medifocus Guidebook on Myelodysplastic Syndromes click here

To subscribe to additional FREE Medifocus Digest Alert on other disease/condition areas click here

Get the Medifocus Guidebook on Myelodysplastic Syndromes...
at a Special 20% Discount

Medifocus Guidebook on Myelodysplastic Syndromes

Updated: January 6, 2020
193 Pages

This one of a kind Guidebook offers:

  • Answers to your critical health questions including the latest treatments, clinical trials, and expert research.
  • High Quality, Professional level information you can trust and understand culled from the latest peer-reviewed journals.
  • Timely, up to date content with free guidebook updates for 1 year.
  • A unique resource to find leading experts, institutions, and support organizations including contact information and hyperlinks.
  • Over 130,000 Guidebooks Sold
  • 100% Risk Free Money Back Guarantee


The Medifocus Guidebook on Myelodysplastic Syndromes is available in the following two convenient formats:


Soft-cover book that is available for immediate shipping via either U.S. Priority Mail or International AirMail (outside the U.S.).

  • Regular List Price = $36.95
  • Less 20% Discount = - $7.40
  • Discounted Price = $29.55(excluding shipping & handling)

Order the Printed Guidebook


Available for immediate download as a PDF document.

  • Regular List Price = $27.95
  • Less 20% Discount = - $5.60
  • Discounted Price = $22.35

Order the Digital Guidebook

Order by Phone

Call Toll Free in the U.S.

From Outside the U.S.

You can also receive a 20% discount when you order your Guidebook by phone.

To receive your 20% discount, simply mention the Discount Coupon Code below to the customer service representative taking your order.

Discount Coupon Code for
Phone Orders


Coupon Expires: May 8, 2020

What Our Customers Are Saying...

"I purchased the MediFocus Guidebook on Myelodysplastic Syndromes to help my father understand the disease that he has. Doctors in France do not communicate very well the various treatment options neither do they tell you about the prognosis with enough clarity and confidence. We live in France and we believe there is no equivalent in Europe to the service you offer. We have read the Guidebook attentively and have learned a great deal about this condition. The wording is simple enough to be understandable even for non-native English speakers. It was money well spent!"
Saint Ismier, France

"Your MediFocus Guidebook on Myelodysplastic Syndromes has been a valuable companion in providing wise counsel to a beleaguered soul. Many times I was comforted by knowing that I could have my questions answered correctly and completely by using your Guidebook. I wouldn't be without it for anything. Thank you again and again."
Rockville, Maryland

"Your Medifocus Guidebook on Myelodysplastic Syndromes has been extremely valuable to me in understanding the complicated disease that afflicts me. It can be very depressing but to understand it intellectually can be very calming and heartening. Fear of the unknown is most devastating and your Guidebook provides the facts in an understandable way without 'watering-down' the science. Thank you for your outstanding publication."
Los Angeles, California

Medifocus Digest Alert is published by Medifocus, Inc.
3809 Clarks Lane, Suite 100, Baltimore, MD 21215 USA
Copyright © 2020 Medifocus, Inc. All rights reserved.